CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to design and evaluate new dinuclear ruthenium-based anti-cancer drugs that exhibit low toxicity and high selectivity towards cancerous tissues. By exploring the relationship between the structure of these complexes and their biological activity, the project seeks to develop more effective treatments…
Current platinum-based anti-cancer drugs, such as cisplatin, are well established in the successful treatment of various forms of cancer, however, the use of these drugs is significantly limited by associated side effects and drug resistance.
Ruthenium-based alternatives, some of which are in clinical testing, have shown considerable promise, exhibiting low general toxicity alongside selectivity and high activity toward cancerous tissue.This proposal takes advantage of these remarkable properti…
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
